{"id":6359,"date":"2022-09-01T14:52:00","date_gmt":"2022-09-01T09:52:00","guid":{"rendered":"https:\/\/www.serenepharma.com\/?p=6359"},"modified":"2022-10-28T14:52:54","modified_gmt":"2022-10-28T09:52:54","slug":"vildagliptin-yoki-vildagliptin-metformin-kombinatsiyasining-diabetning-nazorat-qilinmaydigan-2-turiga-chalingan-bemorlarda-insulin-qabul-qilishidagi-samaradorligi-xavfsizligi-va-bardoshliligi-omega","status":"publish","type":"post","link":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/vildagliptin-yoki-vildagliptin-metformin-kombinatsiyasining-diabetning-nazorat-qilinmaydigan-2-turiga-chalingan-bemorlarda-insulin-qabul-qilishidagi-samaradorligi-xavfsizligi-va-bardoshliligi-omega\/","title":{"rendered":"Vildagliptin yoki Vildagliptin\/Metformin kombinatsiyasining diabetning nazorat qilinmaydigan 2-turiga chalingan bemorlarda insulin qabul qilishidagi samaradorligi, xavfsizligi va bardoshliligi (OMEGA tadqiqoti)"},"content":{"rendered":"\n

Havola: Ibrohim El Ebrashi, Misrdagi real sharoitlarda insulin terapiyasida Vildagliptin yoki Vildagliptin\/Metformin kombinatsiyasining diabetning nazorat qilinmaydigan 2-turiga chalingan bemorlarda insulin qabul qilishida samaradorligi, xavfsizligi va bardoshliligi: Tadqiqot OMEGA, Diabetes Res Clin Pract.2020 Apr;162:108042. doi: 10.1016\/j.diabres.2020.108042.<\/p>\n\n\n\n

Maqsad: <\/strong><\/strong><\/h3>\n\n\n\n

Misrdagi real sharoitlarda insulin terapiyasida Vildagliptin yoki Vildagliptin\/Metformin kombinatsiyasining diabetning (QD2) nazorat qilinmaydigan 2-turiga chalingan bemorlarda insulin qabul qilishidagi samaradorligi, xavfsizligi va bardoshliligini baholash<\/p>\n\n\n\n

Tadqiqot rejasi:<\/strong><\/strong><\/h3>\n\n\n\n

Ushbu 12 haftalik istiqbolli kuzatuv tadqiqotiga QD2 bo’lgan bemorlar kiritildi. Birlamchi yakuniy nuqta glikatlangan gemoglobinning (HbA1c) boshlang’ichdan 12-haftaga qadar o’rtacha o’zgarishi edi. Ikkilamchi so’nggi nuqtalar tana vaznining o’rtacha o’zgarishini, insulin dozasini va 12 haftadan keyingi xavfsizlikni o’z ichiga oladi.<\/strong><\/p>\n\n\n\n

Natijalar:<\/strong><\/strong><\/h3>\n\n\n\n

A. Vildagliptin va vildagliptin\/metformin bilan davolash guruhida 12-haftada HbA1c darajasida sezilarli pasayish kuzatildi. (1-rasm)<\/p>\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

1-rasm<\/p>\n\n\n\n

  • 12-haftada vildagliptin\/metformin guruhida bemorlarning 27,1% HbA1c <7% ga va vildagliptin guruhida 11,1% ga erishgan (2-rasm).<\/li><\/ul>\n\n\n
    \n
    \"\"<\/figure>\n<\/div>\n\n\n

    2-rasm<\/p>\n\n\n\n

    Ikkala vildagliptin\/metformin guruhida  12-haftada bemorlarning tana vaznida pasayish kuzatildi (p = 0,0055) (3-rasm).<\/p>\n\n\n

    \n
    \"\"<\/figure>\n<\/div>\n\n\n

    3-rasm<\/p>\n\n\n\n

    Vildagliptin\/metformin guruhida insulinning sutkalik dozasi sezilarli darajada pasayishi (p<0,0001) kuzatildi (4-rasm).<\/p>\n\n\n

    \n
    \"\"<\/figure>\n<\/div>\n\n\n

    4-rasm<\/p>\n\n\n\n

    Har ikki guruhda ham nahorga va ovqatdan keyin glyukoza darajasining sezilarli pasayishi kuzatildi. <\/p>\n\n\n\n

    Nahorga (och qoringa) qon plazmasidagi glyukoza darajasi:<\/em><\/strong><\/h4>\n\n\n\n
    • Vildagliptin: 52,7 \u00b1 62,3 mg\/dl (\u0440=0,0023)<\/li>
    • Vildagliptin \/ metformin: 51,43 \u00b1\u00a041,7 mg\/dl (\u0440=0,0001)<\/li><\/ul>\n\n\n\n

      PPG (ovqat qabul qilgandan keyingi glyukoza):<\/em><\/strong><\/h4>\n\n\n\n
      • Vildagliptin: 73,3 \u00b1 91,3 mg\/dl (\u0440=0,0034)\u00a0\u00a0\u00a0<\/li>
      • Vildagliptin \/ metformin: 51,43 \u00b1\u00a041,7 mg\/dl (\u0440=0,0001)<\/li><\/ul>\n\n\n\n

        Tadqiqot davomida jiddiy yon ta’sirlar kuzatilmadi<\/p>\n\n\n\n

        Xulosa <\/strong><\/strong><\/h3>\n\n\n\n

        Vildagliptin  metformin bilan\/metforminsiz insulinga qo’shimcha sifatida glikemiyani nazorat qilish samaradorligini aniqladi va hech qanday gipoglikemik hodisalarsiz yaxshi muhosaba qilindi.<\/p>\n","protected":false},"excerpt":{"rendered":"

        Havola: Ibrohim El Ebrashi, Misrdagi real sharoitlarda insulin terapiyasida Vildagliptin yoki Vildagliptin\/Metformin kombinatsiyasining diabetning nazorat qilinmaydigan 2-turiga chalingan bemorlarda insulin qabul qilishida samaradorligi, xavfsizligi va bardoshliligi: Tadqiqot OMEGA, Diabetes Res Clin Pract.2020 Apr;162:108042. doi: 10.1016\/j.diabres.2020.108042. Maqsad: Misrdagi real sharoitlarda insulin terapiyasida Vildagliptin yoki Vildagliptin\/Metformin kombinatsiyasining diabetning (QD2) nazorat qilinmaydigan 2-turiga chalingan bemorlarda insulin qabul qilishidagi…<\/p>\n","protected":false},"author":1,"featured_media":5970,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"rs_blank_template":"","rs_page_bg_color":"","slide_template_v7":"","inline_featured_image":false,"footnotes":""},"categories":[141],"tags":[176],"class_list":["post-6359","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gazetauz","tag-endokrinologiya"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t